Seeking Alpha


Send Message
View as an RSS Feed
View milachka's Comments BY TICKER:
Latest  |  Highest rated
  • MannKind Is Ripe: Let's Do Big Things, But Fundamentals First [View article]
    I think 50-60% net profit is realistic for Afrezza.

    Here's my calcs:

    Only 4 years ago their operating profit margin was 22%, for a brand new product they should at least get that. SNY has roughly 14% of R&D expenses which shouldn't apply either. Same is probably true for 'non-recurring' and 'others' which account for another 13%.

    Normally only incremental SG&A should apply to Afrezza (such detail is not available yet), but I guess SNY cannot unilaterally stuff costs in there. Overhead should not automatically go to Afrezza. SG&A is roughly 25%. If we assume that SG&A applied to Afrezza will be 15% (which is a lot as they will not need to hire a new salesforce as they already have a diabetes sales force) we come to a profit margin of:

    22% + 14% + 13% + 15% = 62%

    Allowing for my optimism I'll state a range of 50-60% instead of your 35%.
    Aug 26, 2014. 03:19 PM | 1 Like Like |Link to Comment
  • The Inflection Point For Stem Cells: An Interview With Advanced Cell Technology's Management [View article]
    Well, your summary says it all: ACT does not want to supply any real/new info to its shareholders. We have to make do with what anybody who reads ICell already knows and management just tells us to trust them and to make a leap of faith on the viability of their strategy. I for one would like some real info to help me to decide what to do with my ACTC position.


    - Long awaited interim clinical trial results not controlled by ACTC but the peer review process of the prestigious scientific journal.
    - Ongoing CEO search is not focused on the timing but getting the right person for the job.
    - Up-listing to NASDAQ, free of legacy issues, and well capitalized to pursue Phase II is targeted by the end of 2014."
    Jun 20, 2014. 07:53 AM | Likes Like |Link to Comment
  • MannKind's Bearish Remarks Have Investors Rattled [View article]
    You must have missed the AdComm. FDA insists on using HbA1c as their main metric, but real world doctors seem to have another opinion on that.
    Jun 12, 2014. 05:10 PM | 10 Likes Like |Link to Comment
  • Unjustified Valuation And Repetitive Losses [View article]
    You state: "Salesforce generated cash flows from operations of $473 million, reflecting a massive increase of 67% year-over-year. This was partly because of the company's stock-based compensation plan."

    But wouldn't cash flow from the stock based compensation plan (exercising options I presume) count towards cash flows from financing activities, rather than CF from operations?
    May 27, 2014. 05:23 AM | Likes Like |Link to Comment
  • Unjustified Valuation And Repetitive Losses [View article]
    Yawn...Did you say anything that was not already said in these articles?

    - Is A Sell by Seeking Profits • Wed, May. 21
    - Remains My Favorite Short by Michael Blair • Wed, May. 21
    - - Same Story, Solid Top-Line Revenue Growth Combined With Widening Losses by The Value Investor • Wed, May. 21
    - Earnings: Revenue Growth Strategy Continues To Trim Margins by Trefis • Wed, May. 21
    - Is Stumbling A Buy? by Achilles Research • Thu, May. 22
    May 27, 2014. 05:10 AM | Likes Like |Link to Comment
  • Why The Shorts Are Wrong About [View article]
    Come on. CRM already dropped from 65 to 50 after last quarter's earnings report which were very good according to CRM metrics (I am not argueing about validity) which for now have been accepted by the market as the share price shows.

    It was always very unlikely that CRM would be taken down even further after this earnings report which was again very good according to CRM metrics. If anything the drop immediately after earnings was an orchestrated attempt by shorts to take it down (BTW I don't believe that either).
    May 23, 2014. 06:29 AM | Likes Like |Link to Comment
  • Vringo's Shareholder Update And What Investors Need To Know About Patent Reform And This Patent Hero [View article]
    Is the call available somewhere? Or a transcript.

    This day and age you'd expect a cy like Vringo to make the call available on their website.
    Feb 17, 2014. 10:12 AM | Likes Like |Link to Comment
  • The Achilles' Heel Of Apple Is Its Recalcitrant High-Margin Policy [View article]
    You must be kidding. With a standard component such as memory, Apple is not adding any value that warrants such a mark-up. There is no extra effort / know-how involved in installing a 32G instead of a 16G memory chip.

    The cost of memory has decreased 71% over the last 4 years, but Apple keeps charging the same amount.

    Here's a little more detail on the issue.
    Jan 7, 2014. 08:34 AM | 1 Like Like |Link to Comment
  • The Achilles' Heel Of Apple Is Its Recalcitrant High-Margin Policy [View article]
    A 16G iPad costs €479 and an 18G iPad costs €569, so I am paying €90 for an extra 16G which probably cost less than €5 to Apple.

    If that is the way they generates their 40% margins I feel I am being taken advantage of.

    That is why I only have 1 Apple product (iPad 2).
    Jan 7, 2014. 07:03 AM | Likes Like |Link to Comment
  • MannKind Corporation: One Large Step For Shareholders, One Gigantic Step For Diabetics [View article]
    Great article, but I already read it about a month ago:

    MannKind Corporation: One Large Step for Shareholders, One Gigantic Step for Diabetics
    by Marcelo Zinn on December 11, 2013
    Jan 6, 2014. 08:22 AM | 5 Likes Like |Link to Comment
  • Vringo Gets Second Injunction Against ZTE: A Global Licensing Agreement Looks Imminent Now [View article]
    A couple of questions:

    - Do you expect Vringo to start approaching other manufacturers on the back of the litigiation successes against ZTE?
    - Do you have a ball park number for the monetary value of a global deal with ZTE?
    - By what number could we multiply that number to valuate the potential with other manufacturers?
    Dec 19, 2013. 07:10 AM | 1 Like Like |Link to Comment
  • JDS Uniphase - Stay Away Amidst A Very Poor Track Record [View article]
    I couldn't resist. It was a silly comment to make.
    Dec 12, 2013. 06:00 PM | Likes Like |Link to Comment
  • JDS Uniphase - Stay Away Amidst A Very Poor Track Record [View article]
    "While the company operates in a long term growth industry, JDSU appears to be not raping the fruits from doing so."

    Glad they have some standards. I definitely would not buy a company that is raping the fruits.
    Dec 12, 2013. 10:55 AM | Likes Like |Link to Comment
  • Potash Turmoil Creates Investment Opportunities [View article]
    Coldcall, how can you say that AGU was dumped as much as the others? AGU is down roughly 5% since the Uralkali announcement while POT and MOS are still down over 20%.;range=1m;compare=potn...

    BTW, I selected MOS to invest in. The company will buy back a lot of shares from the Cargill shareholders in November and this event gives them the opportunity to do that on the cheap. So for all I care, MOS can hover at this level until the end of 2013.
    Aug 21, 2013. 05:25 AM | 2 Likes Like |Link to Comment
  • My Thoughts On Vringo Insider Stock Sales [View instapost]
    Shouldn't you include Berger's indirect holdings of 1,800,000 shares when you're calculating the percentage of his position he sold? According to me he only sold about 10%.
    Nov 19, 2012. 05:29 AM | Likes Like |Link to Comment